Kenn L. Zerivitz

595 total citations
6 papers, 460 citations indexed

About

Kenn L. Zerivitz is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kenn L. Zerivitz has authored 6 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 1 paper in Pulmonary and Respiratory Medicine. Recurrent topics in Kenn L. Zerivitz's work include Hedgehog Signaling Pathway Studies (4 papers), Cancer-related Molecular Pathways (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Kenn L. Zerivitz is often cited by papers focused on Hedgehog Signaling Pathway Studies (4 papers), Cancer-related Molecular Pathways (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Kenn L. Zerivitz collaborates with scholars based in United States and Switzerland. Kenn L. Zerivitz's co-authors include Jennifer A. Low, Mitesh J. Borad, Charles M. Rudin, Walter C. Darbonne, Ilsung Chang, Patricia LoRusso, Richard Graham, Daniel D. Von Hoff, Christine L. Hann and Raoul Tibes and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kenn L. Zerivitz

6 papers receiving 437 citations

Peers

Kenn L. Zerivitz

MB

ONCOL

EPIDE

DERMA

PFM

Bann‐Mo Day United States

Maja Sabol Croatia

Henry Haskell United States

Shelley Ji Eun Hwang Australia

Eiki Sakai Japan

Debra Mikkola United States

Heather Geiger United States

Shin Taek Oh South Korea

Adriana T. Lopez United States

Melissa D. Gordon United States

Bann‐Mo Day United States

Kenn L. Zerivitz

194 ×0.5

MB

132 ×0.9

ONCOL

109 ×1.0

EPIDE

124 ×1.2

DERMA

54 ×0.8

PFM

Citations per year, relative to Kenn L. Zerivitz Kenn L. Zerivitz (= 1×) peers Bann‐Mo Day

Countries citing papers authored by Kenn L. Zerivitz

Since Specialization

Citations

This map shows the geographic impact of Kenn L. Zerivitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenn L. Zerivitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenn L. Zerivitz more than expected).

Fields of papers citing papers by Kenn L. Zerivitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenn L. Zerivitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenn L. Zerivitz. The network helps show where Kenn L. Zerivitz may publish in the future.

Co-authorship network of co-authors of Kenn L. Zerivitz

This figure shows the co-authorship network connecting the top 25 collaborators of Kenn L. Zerivitz. A scholar is included among the top collaborators of Kenn L. Zerivitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenn L. Zerivitz. Kenn L. Zerivitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Graham, Richard, Ilsung Chang, Jin Y. Jin, et al.. (2012). Daily Dosing of Vismodegib to Steady State Does Not Prolong the Qtc Interval in Healthy Volunteers. Journal of Cardiovascular Pharmacology. 61(1). 83–89. 9 indexed citations

2.

LoRusso, Patricia, Charles M. Rudin, Josina C. Reddy, et al.. (2011). Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(8). 2502–2511. 420 indexed citations

3.

Bendell, Johanna C., Lowell L. Hart, Irfan Firdaus, et al.. (2010). Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 28(15_suppl). 3530–3530. 10 indexed citations

4.

Hoff, Daniel D. Von, Charles M. Rudin, Patricia LoRusso, et al.. (2008). Abstract LB-138: Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients. Cancer Research. 68(9_Supplement). LB–138. 10 indexed citations

5.

Wright, James R., Kenn L. Zerivitz, & Mason Schoenfeldt. (2003). Clinical trials referral resource. Current clinical trials of bortezomib.. PubMed. 17(5). 677–80, 683. 4 indexed citations

6.

Wright, James R., Kenn L. Zerivitz, Amy Gravell, & Bruce D. Cheson. (2002). Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra).. PubMed. 16(7). 930–1, 935. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact